LONDON, May 2, 2026, 18:02 BST
- Halma shares rose 2.72% on Friday to 4,527p, outperforming a weaker FTSE 100 session.
- Cardioline said it acquired Cardios from Halma, adding a fresh portfolio move to the FTSE 100 group’s healthcare story.
- Investors are now looking to Halma’s June 11 full-year results after the company guided for mid-teens organic revenue growth and an adjusted EBIT margin of about 22%.
Halma plc shares pushed close to a record high on Friday, rising 2.72% to 4,527p as the London-listed safety and medical technology group outpaced a softer FTSE 100. The stock ended just 1.15% below its 52-week high, according to MarketWatch.
The move matters now because Halma is entering a results window with a fuller deal pipeline, a higher share price and less room for disappointment. The London market is closed for the weekend, leaving Friday’s rally as the latest test of investor appetite for one of the UK market’s more highly rated industrial technology names.
It also comes as Halma’s healthcare portfolio shifts at the margin. Cardioline, backed by healthcare investor ARCHIMED, said on April 30 it bought Cardios, a São Paulo-based maker of Holter monitoring and ambulatory blood-pressure monitoring products, from Halma; financial terms were not disclosed in the release.
Cardioline Chief Executive Luis Meireles said the deal strengthened the company’s “leadership position in telemedicine” and opened a new geographic hub. Cardios CEO Erica Chriguer said the combination added Cardioline’s stress-test and electrocardiography products to Cardios’s portfolio. Cardioline
For Halma, the sale sits beside a larger buy. On April 13, the company said it had acquired Surgistar, a California-based maker of ophthalmic surgical instruments, for $90 million, or about £67 million, as a bolt-on acquisition for MicroSurgical Technology, its healthcare-sector business.
Halma Chief Executive Marc Ronchetti said cataract and ophthalmic surgery are “long term growth markets” for the group and that Surgistar’s products were “highly complementary” to MST’s range. The language was measured, but the message was clear enough: Halma is still leaning into niche medical devices where ageing populations support demand. Halma
There is a competitive backdrop too. In eye-care devices, Revenio Group is moving to acquire Visionix, while Halma’s Surgistar deal adds to MST’s surgical product base; both moves point to consolidation in specialised ophthalmic equipment rather than broad hospital hardware.
Halma told investors in March it remained on track for mid-teens organic constant-currency revenue growth — meaning sales growth excluding acquisitions, disposals and exchange-rate swings — for the year ended March 31. It also guided for an adjusted EBIT margin, or earnings before interest and tax excluding certain items, of about 22%.
The company said order intake remained ahead of revenue and the prior-year period, and that it had completed five acquisitions in the financial year to date, with record investment of £451 million on a maximum total consideration basis. Full-year results are due on June 11.
But the setup is not one-way. Sterling strength is expected to weigh on translation of overseas revenue into pounds, and analysts have flagged that the next debate is likely to be fiscal 2027 guidance, especially the growth path for Halma’s photonics business, which uses light-based technologies in environmental and analytical applications.
Valuation is another check. Investing.com lists an average 12-month analyst target of 4,032.65p across 17 analysts, below Friday’s close, with estimates ranging from 3,050p to 4,930p. That spread leaves room for support, but also shows the market has already priced in a fair amount of delivery.
Halma’s pitch remains the same: a group of specialist businesses in safety, environment and health, with more than 9,000 employees across over 20 countries and a place in the FTSE 100. The question for June is whether that model can keep turning small deals, steady orders and niche demand into the profit growth investors now expect.
